Alzheimer Disease: Amyvid Debate Over Reimbursement

From Bloomberg: Scientists Back Alzheimer’s Test Amid Doubts Over ValueBy Elizabeth Lopatto - Jun 30, 2013 11:01 PM CT "The U.S. government is set to decide this month whether federal health insurance should cover the cost of a $3,000 test..." Read the news article
Source: BrainBlog - Category: Neurologists Source Type: blogs

Related Links:

Publication date: Available online 20 February 2020Source: Journal of Molecular Graphics and ModellingAuthor(s): Rajneet Kaur Saini, Hema Thakur, Bhupesh GoyalAbstractThe amyloid-β (Aβ) aggregation in the brain has been associated with the development of Alzheimer's disease (AD). The previous studies have reported that Piedmont mutation (L34V) increases the rate of Aβ40 aggregation. However, the underlying molecular mechanism of the effect of L34V mutation on Aβ40 structure, dynamics, and aggregation remains largely unclear. In the present study, molecular dynamics (MD) simulations were performed to elu...
Source: Journal of Molecular Graphics and Modelling - Category: Molecular Biology Source Type: research
The field of Alzheimer's disease research is in the midst of a slow-moving and consequential debate over the role of infection in the development of the condition. The fundamental question is this: in the absence of genetic variants that raise risk, why do only some people progress to full blown Alzheimer's disease? The presence - in only some people - of sufficient degrees of persistent infection is one possible answer to that question. Candidates include herpesviruses, oral bacteria such as P. gingivalis, lyme disease spirochetes, and others. Alzheimer's is a condition characterized by amyloid-β aggregation i...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
FRIDAY, Feb. 21, 2020 -- A proposed project to map the genes of 1 million people in New York living with or at risk for Alzheimer disease was announced Friday by Gov. Andrew Cuomo. He said the five years of data collected by the Curing Alzheimer's...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Abstract Donepezil hydrochloride thermosensitive in situ gel for nasal delivery was prepared by using Poloxamer 407 and Poloxamer 188 as thermoreversible polymers, hydroxypropyl-β-cyclodextrin and ethylparaben as permeation enhancer and preservative, respectively. The gelation temperature and time, pH value of the gel formulation were found to meet the requirements for nasal administration. The in vitro erosion and in vitro release tests exhibited obvious drug sustained release behavior. Meantime, main pharmacokinetic parameters such as tmax, cmax and AUC in plasma as well as in brain were significantly diffe...
Source: Acta Pharmaceutica - Category: Drugs & Pharmacology Authors: Tags: Acta Pharm Source Type: research
The objective of this study is to evaluate the degree of understanding of AD among informal caregivers and different segments of the general population through the Alzheimer’s Disease Knowledge Scale (ADKS).Patients and methodsWe assessed the knowledge of caregivers in different follow-up periods (less than one year, between 1 and 5 years, and over 5 years since diagnosis) and individuals from the general population. ADKS scores were grouped into different items: life impact, risk factors, symptoms, diagnosis, treatment, disease progression, and caregiving.ResultsA total of 419 people (215 caregivers and 204 individu...
Source: Neurologia - Category: Neurology Source Type: research
Conditions:   Alzheimer Disease;   Functional Food;   Subjective Cognitive Decline;   Intervention;   Neuroimaging Interventions:   Dietary Supplement: Mixed functional foods supplementation;   Dietary Supplement: Placebo Sponsor:   XuanwuH 2 Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Nagata T, Shinagawa S, Yoshida K, Noda Y, Shigeta M, Mimura M, Nakajima S Abstract OBJECTIVE: The aim of the present study was to identify individual symptoms whose early improvements contributed to subsequent treatment response to antipsychotics for neuropsychiatric symptoms (NPSs) in patients with Alzheimer's disease (AD) using the dataset of the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD). METHODS: The CATIE-AD study was conducted between April 2001 and November 2004 at 45 sites in the United States. Data for 421 patients with DSM-IV AD with NPSs treate...
Source: Journal of Clinical Psychiatry - Category: Psychiatry Tags: J Clin Psychiatry Source Type: research
DISCUSSION: The estimates could help to inform patients, their families, and policymakers about probable trajectories. PMID: 32072728 [PubMed - as supplied by publisher]
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay: Alzheimer's Gene Mapping Project Proposed in New York State A proposed project to map the genes of 1 million people in New York living with or...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Title: Alzheimer's Gene Mapping Project Proposed in New York StateCategory: Health NewsCreated: 2/21/2020 12:00:00 AMLast Editorial Review: 2/21/2020 12:00:00 AM
Source: MedicineNet Alzheimer - Category: Geriatrics Source Type: news
More News: Alzheimer's | Government | Health | Health Insurance | Insurance | Neurologists